HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: A retrospective study evaluating long-term efficacy and safety.

AuthorsAbdallah Khemis, Awatef Kelati, Henri Montaudié, Jean-Philippe Lacour, Thierry Passeron
JournalJournal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 79 Issue 4 Pg. 758-760 (Oct 2018) ISSN: 1097-6787 [Electronic] United States
PMID29596876 (Publication Type: Evaluation Study, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Receptors, Interleukin-17
  • brodalumab
  • secukinumab
Topics
  • Adult
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Long-Term Care
  • Male
  • Patient Safety
  • Psoriasis (diagnosis, drug therapy)
  • Receptors, Interleukin-17 (antagonists & inhibitors)
  • Recurrence
  • Retreatment
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: